Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Study: Sanofi's Multaq shouldn't be a first-line drug
Study: Sanofi's Multaq shouldn't be a first-line drug
Study: Sanofi's Multaq shouldn't be a first-line drug
Submitted by
admin
on April 6, 2010 - 2:26pm
Source:
Fierce Pharma
News Tags:
Sanofi
Multaq
atrial fibrillation
Headline:
Study: Sanofi's Multaq shouldn't be a first-line drug
Do Not Allow Advertisers to Use My Personal information
